



S2 Fig

Fig S2A




No significant association between the number of missense SNV per megabase and overall survival, with [2.13 \(range 0.038-11.46\)](#) in tumors from those patients who survived greater than 12 months, versus [0.48 \(range 0.019-9.90\)](#) in those who did not ($n=25$, [Mann-Whitney \$p=0.37\$](#)).

Fig S2B




No significant difference between median expressed neoantigens in tumors from patients who survived greater than or equal to 12 months: was [1.31 \(range 0.00-6.06\)](#), versus [0.35 \(range 0.00-5.30\)](#) in those who survived less than 12 months ([n=25, Mann-Whitney p=0.36](#)).

Fig S2C



No significant difference between median predicted neoantigens per megabase: [4.58 \(range 0.037-39.48\)](#) in tumors from patients with DCB, as compared to [1.35 \(range 0.00-20.22\)](#) in those who progressed in less than 6 months (no DCB) ([n=25, Mann-Whitney p=0.55](#)).

Fig S2D



No significant difference between median predicted neoantigens per megabase in tumors from those patients who survived greater than 12 months (here used to define DCB-OS) was [3.56 \(range 0.037-39.48\)](#) as compared to [1.37 \(range 0.00-20.22\)](#) in those who did not (no DCB) ($n=25$, Mann-Whitney $p=0.81$).